Clinical trials: NERD
Non-erosive Gastroesphageal Reflux Disease
Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease
The purpose of this study is to investigate the safety and clinical efficacy of HIP1601 in patients with Non-erosive gastroesphageal reflux disease.
- Trial name
- NCT04325620
- Testing
- HIP1601, HGP1805
- Where
- South Korea
- Volunteers
- 208 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Non-erosive Gastroesophageal Reflux Disease
Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)
The purpose of this study was to evaluate the efficacy and safety of oral TAK-438 10 mg once-daily in the treatment of non-erosive gastroesophageal reflux disease (NERD).
- Trial name
- NCT02954848
- Testing
- TAK-438 10 mg
- Where
- 30 sites in Japan
- Volunteers
- 484 people
- Sponsor
- Takeda
Sleep Disorders, Non-Erosive Reflux Disease
Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders
The aim of the study was to evaluate the effect of pantoprazole on sleep disorders in patients with NERD (non-erosive reflux disease) or eGERD (erosive gastroesophageal reflux disease).
- Conditions
- Sleep Disorders, Non-Erosive Reflux Disease, Gastroesophageal Reflux Disease
- Trial name
- PANDA (NCT00830115)
- Testing
- Pantoprazole
- Where
- 201 sites in Germany
- Volunteers
- 1,045 people
- Sponsor
- Nycomed
Non-erosive Reflux Disease
Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)
Randomized, double-blind, active-controlled, multi-center phase 2 clinical trial to investigate the safety, tolerability and efficacy of YH1885L in patients with non-erosive reflux disease(NERD)
- Trial name
- NCT01750437
- Testing
- YH1885L(Revaprazan), Esomeprazole 20mg
- Where
- 10 sites in South Korea
- Volunteers
- 149 people
- Sponsor
- Yuhan Corporation
Non-erosive Gastroesophageal Reflux Disease
A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease
To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal reflux disease in a multicenter, randomized, double-blind…
- Trial name
- NCT00165646
- Testing
- E3810
- Where
- 35 sites in Japan
- Volunteers
- 288 people
- Sponsor
- Eisai Co., Ltd.
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
The primary objectives of this study are to assess the efficacy of vonoprazan (10 mg and 20 mg once daily [QD]) compared to placebo (QD) in relief of heartburn over 4 weeks in participants with NERD.
- Trial name
- NCT05195528
- Testing
- Vonoprazan
- Where
- 108 sites in United States
- Volunteers
- 776 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Non-erosive Reflux Disease, Non-Erosive Gastro-Esophageal Reflux Disease
Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD)
This study is designed to determine the efficacy and safety of DWP14012 compared to a placebo following a once-daily oral dose of DWP14012 at 20 mg, 40 mg, or placebo for 4 weeks in patients with NERD.
- Conditions
- Non-erosive Reflux Disease, Non-Erosive Gastro-Esophageal Reflux Disease, Non-Erosive Esophageal Reflux Disease
- Trial name
- NCT06121830
- Testing
- DWP14012 20mg, DWP14012 40mg
- Where
- South Korea
- Volunteers
- 324 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Erosive Gastroesophageal Reflux Disease, Non-Erosive Reflux Disease
Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders (PULS)
The aim of the study was to evaluate the effect of Pantoprazole 20 mg/40 mg for 14 days on symptoms in patients with NERD (non-erosive reflux disease) or eGERD (erosive gastroesophageal reflux disease) with special focus on the…
- Trial name
- PULS (NCT00562094)
- Testing
- Pantoprazole
- Where
- 1,153 sites in Germany
- Volunteers
- 8,616 people
- Sponsor
- Nycomed
Gastroesophageal Reflux Disease
Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Symptoms of Non-Erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (eGERD)
The aim of the study was to evaluate the effect of 7 days treatment with Pantoprazole 40 mg and 20 mg on symptoms in patients with NERD (non-erosive reflux disease) or eGERD (erosive gastroesophageal reflux disease) in clinical…
- Trial name
- PANTHER (NCT00561730)
- Testing
- Pantoprazole
- Where
- 259 sites in Germany
- Volunteers
- 1,995 people
- Sponsor
- Nycomed
Gastro-esophageal Reflux Disease
Validation of a Non-invasive In-vitro Diagnostic Test (Peptest) Against Other Diagnostic Methods for GERD
The primary objective of this clinical study is to determine whether Peptest (Human Pepsin lateral flow in vitro diagnostic medical device) is equivalent to other GERD diagnostic methods commonly applied in clinical practice by…
- Trial name
- PEPTESTCN (NCT02456779)
- Testing
- in vitro diagnostic test (Peptest), Questionnaire
- Where
- 9 sites in China
- Volunteers
- 1,032 people, healthy volunteers welcome
- Sponsor
- MAAB (Shanghai) Medical Device Limited
GERD (Gastroesophageal Reflux Disease), NERD
New Topical tReatment Options for Symptomatic patiEnts With Nonerosive gastroesophageaL Reflux dIsease (The RELIEF Trial)
The goal of this randomized, double-blind, single-center clinical trial RELEIF is to learn if medical devices work to decrease symptoms of gastroesophageal reflux disease (GERD) in adults' patients.
- Conditions
- GERD (Gastroesophageal Reflux Disease), NERD, Heartburn, Regurgitation, Gastric
- Trial name
- RELIEF (NCT07624383)
- Testing
- Esophageal barrier medical device
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Cellmedis
Gastroesophageal Reflux
Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Non-erosive Reflux or Gastroesophageal Reflux Disease (BY1023/DE-004)
The aim of the study is to evaluate the effect of pantoprazole on fast symptom reduction in hospitalized patients with NERD (non-erosive reflux disease) or GERD (gastroesophageal reflux disease, Los Angeles [LA] Grade A-D).
- Trial name
- NCT00326027
- Testing
- Pantoprazole
- Where
- 35 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Nycomed
Gastroesophageal Reflux Disease, Non-erosive Reflux Disease
The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)
The aim of the study is to compare two different endpoint measures: heartburn as assessed by the physicians versus gastroesophageal reflux disease (GERD)-related symptoms as assessed by the patient using the ReQuest™…
- Trial name
- NCT00449813
- Testing
- Pantoprazole
- Where
- 15 sites in Netherlands, Switzerland
- Volunteers
- 40 people
- Sponsor
- Takeda
Non Erosive Reflux Disease, Chronic Gastritis
Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients
To compare the symptom control rate between 8 weeks esomeprazole treatment regimen group and 2 weeks esomeprazole treatment regimen group in co-diagnosed NERD and chronic gastritis patients, as evaluated by GerdQ after 24 weeks…
- Trial name
- NCT01119768
- Testing
- Esomeprazole
- Where
- 8 sites in China
- Volunteers
- 305 people
- Sponsor
- AstraZeneca
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
The primary objectives of this study are to assess the efficacy of vonoprazan (10 mg, 20 mg, and 40 mg On-Demand) compared to placebo (On-Demand) in relief of episodic heartburn over 6 weeks in participants with symptomatic…
- Trial name
- NCT04799158
- Testing
- Vonoprazan
- Where
- 63 sites in United States
- Volunteers
- 458 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Gastroesophageal Reflux
Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD occurs when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the…
- Trial name
- NCT00163306
- Testing
- Pantoprazole
- Where
- 79 sites in Austria, Germany and 2 more
- Volunteers
- 1,200 people
- Sponsor
- Takeda
Non-erosive Reflux Disease
Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population
The purpose of this study is to study safety and efficacy of omeprazole standard treatment in a Japanese non-erosive reflux disease population.
- Trial name
- NCT00259077
- Testing
- Omeprazole
- Where
- 26 sites in Japan
- Volunteers
- 270 people
- Sponsor
- AstraZeneca
Non-erosive Gastroesophageal Reflux Disease
A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease
To investigate esophageal reflux condition in patients with non-erosive gastroesophageal reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week treatment with 5 mg/day or 10 mg/day of E3810…
- Trial name
- NCT00165672
- Testing
- RABEPRAZOLE SODIUM
- Where
- 13 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Eisai Inc.
The Aim of This Study is to Investigate the Frequency and Related Risk Factors of Recurrence, and Quality of Life in Patients With GERD After Treatment With PPI
Recurrence Rate, Risk Factors for the Recurrence, and Quality of Life in Patients With GERD in Korea-an Observational
Recurrence rate, risk factors for the recurrence, and quality of life in patients with GERD in Korea-an observational study.
- Trial name
- Refresh (NCT01378338)
- Where
- 10 sites in South Korea
- Volunteers
- 855 people
- Sponsor
- AstraZeneca
Non-erosive Reflux Disease
A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population
The purpose of this study is to investigate the pharmacodynamic effect of omeprazole n a Japanese non-erosive reflux disease population
- Trial name
- NCT00259051
- Testing
- Omeprazole
- Where
- 13 sites in Japan
- Volunteers
- 40 people
- Sponsor
- AstraZeneca